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ABSTRACT: Anticancer therapeutic intervention in patients with
solid tumours still relies on the necessity of empirically treating
many patients to obtain benefit for a limited few. The activity of
a given drug in patients with advanced cancer is the result of a
pharmacodynamic interaction with a pathway. Such putative
pathways must be both prevalent in the cancer cells and relevant
to the process of uncontrolled cell proliferation. Several examples
have clearly demonstrated the value of measuring the molecular
target and using it as inclusion criteria for clinical trials. Adaptive
trial designs and the definition of clinical surrogate end-points
can be helpful tools to further improve clinical drug development.
In general go/no go decisions must be established prospectively.
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Anticancer therapeutic intervention in patients with solid
tumours still relies on the necessity of empirically treating many
patients to obtain benefit for a limited few. The activity of a given
drug in patients with advanced cancer is the result of a pharma-
codynamic interaction with a pathway. Such putative pathways
must be both prevalent in the cancer cells and relevant to the pro-
cess of uncontrolled cell proliferation.
Many molecularly targeted anticancer agents have demon-
strated limited effectiveness thus far. An example is the marginal
impact on overall survival of erlotinib (Tarceva), an epidermal
growth factor receptor inhibitor, after first- or second-line treat-
ment, compared to placebo. The respective study involved 731
patients with advanced non-small-cell lung cancer (NSCLC).1
After adjusting for stratification factors and epidermal growth
factor receptor (EGFR) status, the survival curves for the two treat-
ments started to diverge after 2 or 3 months. At 1 year, 31% of
patients treated with erlotinib were still alive, compared with
22% of those on placebo.
Similarly, new therapeutic schemes for treating hormone-
refractory prostate cancer have shown only limited effects on
overall survival. In one study involving 674 men, the median over-
all survival was 17.5 months in the group given docetaxel and est-
ramustine, and 15.6 months in those given mitoxantrone and
prednisone. The corresponding hazard ratio for death was 0.80.2
DESIGNING TRIALS: One way to streamline clinical trials of new
anticancer agents is to use biomarkers rather than clinical end-
points. Several examples of novel markers for assessing effective-
ness and predicting response to therapy were discussed.
Methylation-dependent transcriptional silencing of 14-3-3r, a
major G2-M checkpoint control gene, could be a new, indepen-
dent prognostic factor for survival in NSCLC patients receiving
platinum-based chemotherapy.3 14-3-3r methylation was
observed in all histologic types of 39 patients (34%). And median
survival was significantly longer in the methylation-positive
group (15.1 versus 9.8 months). Median time to progression was
8 months in the methylation-positive group and 6.3 months in
the methylation-negative group. Furthermore, 14-3-3r methyla-
tion might be a prognostic marker. The estimated survival rate
at 18 months was 64% amongst methylation-positive responders
and 21% amongst methylation-negative responders. Methylation-
negative responders had a fourfold greater risk of death during
follow-up than those who were methylation-positive. Addition-
ally, translational research studies in advanced NSCLC are limited
by a lack of tumour biopsy tissue, but methylation of 14-3-3r can
be reliably and conveniently detected in the serum, thus obviat-
ing the need for tumour tissue analysis in translational studies.
As another example trabectedin (Yondelis) induced long last-
ing responses and tumour control in a clinically relevant propor-
tion of sarcoma patients resistant or relapsed to conventional
chemotherapy.4 After the EMEA/CHPM positive opinion and
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approval from the European Commission, Yondelis is now the
gold standard for patients with advance soft tissue sarcoma
pre-treated with conventional therapy.5 Its mechanism of action
is based on binding to the DNA minor groove, causing the helix
to bend. By interacting with transcription factors and other
DNA-binding proteins, it interferes with DNA repair pathways
through S-phase delay and G-2 blockade.6
In one large phase II study, durable objective responses to tra-
bectedin were obtained in a subset of sarcoma patients with dis-
ease progression despite prior chemotherapy.7 Such phase II
results have been validated in a comparative trial that has been
the basis of the EMEA positive opinion for Yondelis in advanced
pre-treated soft tissue sarcoma.8 Interestingly the antitumour
activity of trabectedin might be the result of a molecular mecha-
nism related to its interaction with an aberrant transcriptional
regulator. In this context Mixoid round cell liposarcoma (MRCL)
is representative example of a translocation, t 12:16, leading to
a chimeric fusion protein (FUS-CHOP) that acts as a transcription
factor to promote undifferentation and controlled proliferation.
A multi-institutional integrated analysis of a cohort of 34
patients, heavily pretreated with standard therapies for advanced
MRCL was highlighted.9 Amongst patients who received trabect-
edin, 86% achieved long-lasting objective remissions and tumour
control. The median progression-free survival (duration of
tumour control) was 14 months. The molecular basis of these
impressive results are active under investigation. Both the clinical
impact and the pattern of response noted suggested a targeted
mediated effect. This warrants further investigation in other
tumour types, such as prostate cancer, in which a similar molec-
ular signature, translocation leading to a transcription factor can
be identified as a proportion of cases.
In such retrospective analysis9 Grosso and colleagues also
reported on the utility of a measure of tissue response combined
with standard dimensional criteria in the initial assessment of
patients with advanced MRCL treated with trabectedin.1 Tissue
response (i.e. initial tumour response) was defined as either a
decrease in contrast enhancement on magnetic resonance imag-
ing (MRI) or a decrease in contrast uptake or in density measured
in Hounsfield units on computed tomography (CT). Tissue
response is often followed by delayed response. This pattern of
response, that mimicks the one applicable to imatinib in GIST,
has to be considered in the incorporation of response criteria into
prospective studies with trabectin.
Of note patients with advanced MRCL, treated with trabect-
edin and who had the type III FUS-CHOP fusion protein variant
resulting from a translocation mutation (13% of patients in the
study reported by Grosso et al.9) were more likely to have disease
progression than those with other FUS-CHOP translocations.
They also had much shorter median progression-free survival
times.9 The clinical impact of Trabectin in unselected pre-treated,
non MRCL, soft tissue sarcoma patients have been also
reported.10 The data showed a 19% rate of tumour response, with
remissions noted in different sarcoma subtypes. Long-lasting
tumour control was reported in 21% if patients studied. These
findings support the conclusion that trabectin efficacy is not
testricted to MRCL patients.
POTENTIAL ROLE OF DNA REPAIR MECHANISMS: In experimen-
tal models the functionality of DNA repair mechanisms influ-
ences the cyctotoxicity of trabectin and, hence, its efficacy.6 If
either the nucleotide excision repair (NER) is proficient or the dou-
ble-stranded break (DSB) repair mechanism is deficient, the cyto-
toxicity of trabectedin is generally increased. Scho¨ffski et al.
selected ERCC1 and XPD as key genes for NER and BRCA1 for
DSB and characterised their mRNA expression levels as potential
biomarkers for patient outcome in tumour tissues from
advanced, pretreated sarcoma patients exposed to trabectedin.11
Patients with higher levels of ERCC1 or XPD expression showed
a trend toward better clinical outcomes. Low expression of BRCA1
correlated with better relative risk, tumour control, progression-
free survival at 6 months and median survival. Co-expression of
BRCA1 and ERCC1 increased the accuracy of treatment outcome
prediction, identifying the most sensitive subpopulation. Those
with low BRCA1 and high ERCC1 expression demonstrated the
best response and had longer median survival. This group
accounted for 25% of the whole population. Co-expression of
BRCA1 and XPD produced an equivalent prediction of response
to trabectedin. Co-expression of all three markers further refined
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Fig. 1 – A potential design for a phase II trial for a given drug in a particular tumour type based on a molecular signature.
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